Most regen practices review their marketing against the FDA and the FTC and stop there. Medical board advertising rules are a third layer, and the board is the one that holds the license. This guide covers six traps that show up again and again in state board rules. Florida is the worked example of the six states that require a fixed stem cell notice in ads.
TLDR: Medical board advertising rules sit on top of federal law, and they reach the physician personally. Six traps recur across states: testimonials, specialty and certification claims, before-and-after images, fee offers, marketing by or for unlicensed people, and practice names that mislead. Florida now requires a fixed notice in the ads of physicians who offer stem cell therapy under its statute. Each trap ends with one instruction: ask your board. Read on for the six traps, a simple check, and a patient video that both the FTC and the board would flag.
Important Note
This article is for educational purposes only and does not constitute legal, medical, or regulatory advice. Marketing strategies discussed should be reviewed by qualified legal counsel before implementation, particularly regarding FDA, FTC, and state-specific advertising regulations. Regen Portal is a marketing and consulting company, not a law firm. Nothing here implies FDA approval of any product or any use. Most cell, tissue and exosome products marketed to patients are not FDA approved, and the few cell-based products the FDA has approved are approved only for specific labeled indications. Nothing here promises a marketing or business outcome. Regulations change and enforcement varies by state. Confirm current requirements with qualified legal and compliance counsel before you act on anything you read here.
Physicians who want to add cells or tissue ask me about the state first. Is it legal here? Where do I get it? What can I charge? The state question is the right instinct. The answer most of them go looking for, though, is an FDA answer, and the medical board never enters the conversation.
That gap is where medical board advertising problems start. The FDA regulates the product. The FTC regulates the claim. The board regulates the physician, and it reads the website as a statement by a licensee.
This post lays out six traps that recur across state board rules. It stays general, because every state writes its own rule. Florida is the worked example. Counsel and your board decide your own case.
Why Medical Board Advertising Rules Sit on Top of the FDA and FTC
Medical board advertising rules matter because the board acts on the license, not the ad. A state board can restrict, suspend, or revoke the license the whole practice runs on.
Most state practice acts let the board discipline a physician for false or misleading ads. The wording differs by state. Some boards add rules on testimonials, fees, specialty claims, and photos. Others use the general standard and decide case by case.
A federal review looks at the claim. A board looks at the physician behind the claim, even if a marketer wrote it. That is why our compliance review for practices reads every page with three readers in mind: the FDA, the FTC, and the board. The six traps below are where the third reader finds what the first two missed.
The Six Medical Board Advertising Traps
The six traps are testimonials, specialty claims, before-and-after images, fee offers, marketing by or for unlicensed people, and practice names. Each one looks harmless from inside and ends the same way: ask your board.
Trap 1: Testimonials and Patient Endorsements
A testimonial is a claim the physician now owns. The FTC’s endorsement guides Q&A says that if an endorser’s results are not proven typical, the ad must make clear what results people can generally expect. It also says unexpected ties between endorser and marketer must be disclosed. That is the federal floor.
Some boards go further. They limit testimonials, add conditions, or treat a patient’s words about results as the physician’s own claim.
Almost none of the exposure we find in clinic marketing was put there on purpose. A lot of it sits outside the copy, such as testimonials published without the material-connection disclosure. Our guide to compliant review requests covers the federal side. Ask your board whether testimonials are allowed, and on what terms.
Trap 2: Specialty and Certification Claims
The board reads “specialist” and “board certified” as claims about a license it issued. Some boards limit which certifying bodies an ad may cite. Some require the board name and specialty next to the words. A course is not a certification.
“FDA registered clinic” belongs here too. It is the credential claim we see most often on regen sites. It is not a credential, and a board can read it as an implied approval claim. Our post on credential claim rules covers what a team page may say. Ask your board what it allows next to “certified.”
Trap 3: Before-and-After Imagery
A before-and-after photo is a results claim without a sentence. Some boards set rules for these images, such as consent, no editing, or a results-vary note. Others apply the general misleading standard.
For a regen service line, the photo implies an outcome for a product with no approved claim. That is an FDA and FTC problem before it is a board problem. Ask your board whether photos are allowed and what consent and disclosure it expects.
Trap 4: Fee Advertising and Special Offers
Fee ads draw board attention because the advertised fee has to be the real fee. Some boards require a price to state what it includes. Some have rules for “free” and time-limited offers. A “free consult” with hidden conditions is the common failure.
How the offer gets paid for matters too. Many states have separate rules on paying for referrals and fee splitting. A board can read a lead vendor’s per-patient fee that way, and counsel decides that question. Ask your board what a fee ad must include.
Trap 5: Marketing by or for Unlicensed People
The physician answers for ads run in their name, even when someone else made them. An agency, a management company, an unlicensed owner, or a lead vendor can write the ad. The board still sees a licensee’s ad.
The opposite case is worse. An ad that presents an unlicensed person as a provider can raise the question of unlicensed practice. Many practice acts treat aiding it as its own ground for discipline. Ask your board who may advertise medical services in your state.
Trap 6: Practice Names and Titles That Mislead
A practice name is an ad. “Institute,” “center of excellence,” or “Dr.” for a person with no doctorate all invite a question. Some boards review practice names or limit which titles may follow a name.
The name should say what the practice is, and the title what the license is. Ask your board which names and titles it restricts. Next comes a working check.
How to Check Your Own Marketing Against Medical Board Advertising Rules
Read your state practice act and your board’s ad rule first. Then check every page against the six traps.
Step one is the source. Find your state’s medical practice act and the board rule on ads. If you have osteopathic physicians, find that board’s rule too, since it is often a separate chapter.
Step two is the inventory. List every live page, ad, caption, email, and video. Add your Google Business Profile and any vendor landing page that carries your name.
Step three is the six-trap pass. Mark which traps each item touches.
Step four is the question list. Every trap that touched a page becomes one plain question for the board or counsel.
Step five is ownership. After a compliance review, the practice owns the result. Keeping it current stays with the practice or its counsel, unless the practice is on a retainer, in which case we help keep it updated as new laws land. Decide now who reads the board’s rule changes each year. Florida shows why.
Florida Shows What a State-Specific Disclosure Looks Like
Florida added a stem cell ad notice to its practice acts in 2025, in section 458.3245 for medical physicians. Section 459.0127 carries the same rule for osteopathic physicians. Both carry the same title, “Stem cell therapy,” and the same notice. In 2026, Florida added a separate notice for podiatric physicians in section 461.011, with its own wording. Utah, Tennessee, Vermont, Washington, and Georgia have fixed notices of their own.
The statute lets a physician perform stem cell therapy not approved by the FDA in some cases. The therapy must be within the physician’s scope. It must relate to orthopedics, wound care, or pain management. The statute also sets sourcing rules for the cells.
Subsection (5) of the statute covers ads. A physician who conducts stem cell therapy under the section must include this notice in any form of advertisement: “THIS NOTICE MUST BE PROVIDED TO YOU UNDER FLORIDA LAW. This physician performs one or more stem cell therapies that have not yet been approved by the United States Food and Drug Administration. You are encouraged to consult with your primary care provider before undergoing any stem cell therapy.”
The type-size rule is the part that catches marketers. The notice must be clearly legible and no smaller than the largest type in the ad. In practice, that likely means the notice on a web page is at least as big as the headline. Counsel confirms.
The statute also says a violation may subject the physician to board discipline. A federal review does not check for a Florida notice. Our Florida law breakdown covers the rest of the statute. Our post on state stem cell marketing laws tracks other states. Counsel reads your own state’s chapter. The mistakes below survive most federal reviews.
The Mistakes That Survive an FDA and FTC Review
The most common mistake is stopping at the federal review. The copy is clean and everyone relaxes. Nobody opened the state practice act.
The second mistake is the reposted review. A five-star review from a third-party site, reposted on the practice’s own site, becomes a testimonial in its ad. The FTC’s consumer review rule already bars paying for reviews that express a particular sentiment. A board rule on testimonials can reach the repost too. Our reputation management guide covers reviews.
The third mistake is the vendor page. A lead vendor builds a landing page with the physician’s name and a price. The practice never reads it. The board reads it as the physician’s ad.
The fourth mistake is the old rule. The practice checked the board rule the year it opened and never again. Florida in 2025, then Georgia and Tennessee in July 2026, showed how a statute can add a notice. The scenario below shows what a partial review misses.
Picture a Practice Whose Testimonial Check Stopped at the Disclosure
Picture an orthopedic practice in a mid-sized city that added a cell-based service line. Counsel reviewed the site for FDA claims and removed every “treats” and “heals.” The team then added a disclosure to each testimonial and called the FTC check done.
Then a complaint reached the state board about one patient video on the homepage. In it, the patient described her results in her own words. The practice had a signed release and a note that she was not paid.
The disclosure covered her tie to the practice, not her results. Under the FTC guides, a results testimonial needs proof that those results are typical. Without that proof, the ad must clearly say what results people generally get. The practice had neither, and no approved claim exists for the product. A full FTC review would have flagged the video.
The board adds its own layer. In this picture, the state’s rule treats a patient’s words about results as the physician’s own claim. Either way, the practice posted the video, so the practice owns the claim.
The practice pulled the video and answered through counsel. It now reads every testimonial for its results claim, not only for a disclosure. It also keeps a one-page list of its board’s ad rules next to its FDA and FTC checklists. That is medical board advertising compliance in practice: a third reader, added on purpose.
Frequently Asked Questions
Do Medical Board Advertising Rules Apply to Regen Clinics?
Yes, wherever a licensed physician’s name is on the marketing. State boards regulate physician ads through the practice act and their own rules. The rules apply to the physician, not to the product type. Counsel reads the rule for your state.
Can a Regen Practice Use Patient Testimonials?
Under federal law, yes, with the disclosures the FTC requires. A testimonial that describes results also needs proof those results are typical, or a clear statement of what results people generally get. Under state board rules, it depends on the state. Some boards allow them with conditions. Some treat a patient’s words about results as the physician’s own claim. Ask your board before you publish one, and keep a signed release and the disclosure on file.
What Does Florida Require in Stem Cell Advertising?
Florida’s sections 458.3245 and 459.0127 require a physician who conducts stem cell therapy under those sections to put a fixed notice in any form of advertisement. The notice says the physician performs stem cell therapies not yet approved by the FDA. It must be clearly legible and no smaller than the largest type in the ad.
Is the Physician Responsible for Ads a Marketing Agency Wrote?
In most states, yes. The board regulates the licensee, and an ad in the physician’s name is the physician’s ad. That covers agency work, management company campaigns, and lead vendor pages. Read every page that carries the physician’s name before it goes live.
How Often Should a Practice Recheck Its Board’s Advertising Rules?
At least once a year, and whenever the state passes a law that touches the service line. Florida added its stem cell notice in 2025. A practice that last read its board’s rule at opening would have missed it. Assign one person, or counsel, to own the yearly read.
Key Takeaways
- Medical board advertising rules are a third layer on top of the FDA and the FTC, and the board holds the license.
- Testimonials, specialty claims, photos, fee offers, unlicensed marketing, and practice names are the six recurring traps.
- The physician answers for ads in their name, even when an agency or lead vendor wrote them.
- Florida requires physicians who offer stem cell therapy under its statute to carry a fixed notice in their ads, no smaller than the largest type.
- A disclosure is not proof: a results testimonial needs substantiation or a clear statement of generally expected results, and the board adds its own rules.
- Read your state practice act and board rule once a year, and send every trap that touches a page to counsel or the board.
Questions?
If your site has been through an FDA and FTC review, you are ahead of most of the market. The board pass is the one that usually has not happened. We add it to every compliance review we run through Regen Portal, because the board can act on the license.
We do not interpret your state’s practice act. We make sure every page with your name on it has been read against it, with the questions for counsel written down.
PS: If you want to know which of the six traps your site falls into before a board reviewer does, send the URL over for a free compliance audit.
Email: hello@regenportal.com
YouTube: Subscribe to the channel
About Regen Portal
Regen Portal is a marketing and consulting company built for the regenerative medicine industry. We handle practice consulting, marketing compliance, search engine optimization, content creation, social media management, paid advertising, website development, branding, and AI and ops consulting for clinics, manufacturers, distributors, and independent providers. For more on me and how we work, visit Regen Portal and contact us.
About the Author
Oscar Tellez is the founder of Regen Portal, a marketing and consulting company built for the regenerative medicine industry. He has been in this industry since 2015. He started in medical sales and has worked with PRP since 2016. He has reached hundreds of practices and over 200 doctors through sales, teaching and marketing. He holds a B.S. in Exercise Science and Health Promotion from Florida Atlantic University.
